KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers

A4 Study Team, Insight 46 Study Team, Australian Imaging Biomarkers and Lifestyle (AIBL) Study, Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


KLOTHO∗VS heterozygosity (KL∗VSHET+) was recently shown to be associated with reduced risk of Alzheimer's disease (AD) in APOE∗4 carriers. Additional studies suggest that KL∗VSHET+ protects against amyloid burden in cognitively normal older subjects, but sample sizes were too small to draw definitive conclusions. We performed a well-powered meta-analysis across 5 independent studies, comprising 3581 pre-clinical participants ages 60–80, to investigate whether KL∗VSHET+ reduces the risk of having an amyloid-positive positron emission tomography scan. Analyses were stratified by APOE∗4 status. KL∗VSHET+ reduced the risk of amyloid positivity in APOE∗4 carriers (odds ratio = 0.67 [0.52–0.88]; p = 3.5 × 10−3), but not in APOE∗4 non-carriers (odds ratio = 0.94 [0.73–1.21]; p = 0.63). The combination of APOE∗4 and KL∗VS genotypes should help enrich AD clinical trials for pre-symptomatic subjects at increased risk of developing amyloid aggregation and AD. KL-related pathways may help elucidate protective mechanisms against amyloid accumulation and merit exploration for novel AD drug targets. Future investigation of the biological mechanisms by which KL interacts with APOE∗4 and AD are warranted.

Original languageEnglish
Pages (from-to)123-129
Number of pages7
JournalNeurobiology of Aging
StatePublished - May 2021


  • Alzheimer's disease
  • Amyloid
  • APOE4
  • Heterozygosity
  • PET
  • Pre-clinical


Dive into the research topics of 'KL∗VS heterozygosity reduces brain amyloid in asymptomatic at-risk APOE∗4 carriers'. Together they form a unique fingerprint.

Cite this